Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703923 · ClinicalTrials.gov registry record · Phase 2
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
A Phase 2 study, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT01703923: Completed Phase 2 study, sponsored by Avalo Therapeutics.
NCT01703923 is a Phase 2 study that has completed, run by Avalo Therapeutics. The registered enrollment target is 83 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01703923, a Phase 2 study, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.
Primary Outcome
Change in start-to-end difference in cough count, active vs. placebo treatment periods
Interventions
- DRUG placebo
- DRUG FP01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01703923 record still lists
NCT01703923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01703923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01703923 about?
NCT01703923 is a clinical study titled "An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough". The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.
What is the current status of trial NCT01703923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2012-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01703923?
The interventions under investigation include: placebo (DRUG), FP01 (DRUG).
Who is sponsoring clinical trial NCT01703923?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01703923's enrollment target sits among peer trials
83 828th of 2000 higher than 1,171 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia